JUN and breast carcinoma: Here, the authors report that the NOS inhibitor, L-NMMA, sensitises metaplastic breast cancer to a selective PI3K inhibitor, alpelisib, and taxane chemotherapy via repression of c-JUN mediated epithelial-to-mesenchymal transition.